

5

SBF-CM
Folder Details

Folder ID: 120220

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 03/22/2012
Received: 3/12/2012
Date Sent: 3/22/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota Increase for hydrocodone

Signature: B. Boockholdt

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

03/19/2012 3/19/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

Memorandum



Subject

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date

MAR 12 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From

Christine A. Sannerud for
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	Date MAR 16 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From
Barbara J. Bookholdt
Barbara J. Bookholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On March 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-two (92) of (b)(4) customers as well as an in-depth investigation of (b)(4).

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Retired

Based upon a review of (b)(4) customers, ODG recommends that ODQ limit the quota granted to this company. (b)(4) has five (5) customers that are Under Review/Investigation and one (1) that is retired.

We are available to discuss quantitative levels at your convenience. If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

**SBF-CM
Folder Details**

Folder ID: 120391

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 03/30/2012
Received: 3/20/2012
Date Sent: 3/22/2012

Security: A-AES
Abstract: Unit Dose 2012 procurement quota increase for oxycodone memo
Signature: B. Boockholdt

Response:

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

03/29/2012 3/21/2012

Action: Recommendation and Comments
Requested Activity:
Response Notes:

Memorandum



Subject

Unit Dose (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)


Date

MAR 20 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From


Christine A. Sanzerud, Ph.D.
Chief
UN Reporting & Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject Unit Dose (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN:630-08.2)	Date MAR 21 2012
--	-----------------------------------

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 20, 2012, this section received your memorandum requesting a review of Unit Dose's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Unit Dose provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Unit Dose for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

**SBF-CM
Folder Details**

Folder ID: 120920

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 04/27/2012
Received: 4/17/2012
Date Sent: 4/23/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota increase request for oxycodone

Signature: C. Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/24/2012 4/23/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

4/29/2015 9:16:07 AM

1


Memorandum



<p>Subject</p> <p>(b)(4)</p> <p>2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)</p>	<p>Date</p> <p>APR 17 2012</p>
---	--------------------------------

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From 
Christine A. Sannerud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

APR 20 2012

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From

Barbara J. Bobekholdt
Barbara J. Bobekholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On April 17, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and twenty-five (125) of (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Suspension

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Retired

(b)(4);(b)(7)(E)

Retired

(b)(4);(b)(7)(E)

Retired

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. One of (b)(4) customer is currently under (b)(4);(b)(7)(E) (b)(4) fourteen (14) customers are under Review/Investigation; and three (3) are retired.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

5

**SBF-CM
Folder Details**

Folder ID: 120811

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To: Barbara Boockholdt

Location: ODEQ
Due: 04/22/2012
Received: 4/12/2012
Date Sent: 4/25/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota increase request for hydrocodone

Signature: Christine Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/19/2012 4/24/2012


Action: Recommendation and Comments
Requested Activity:
Response Notes:

Memorandum



Subject	Date
(b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	APR 12 2012

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From 
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject <div style="border: 1px solid black; padding: 2px;">(b)(4);(b)(7)(E)</div> 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	Date APR 23 2012
---	---------------------------------------

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Bockholdt
Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On April 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-nine (99) of (b)(4) customers as well as on (b)(4)

The following information was found on (b)(4) and the below listed customers:

Order to Show Cause Requested

(b)(4);(b)(6);(b)(7)(C);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Because four of (b)(4) customers are currently under review/investigation and [Redacted]
[Redacted] ODG recommends that ODQ adjust the quota allotted to (b)(4) accordingly.

(b)(4);(b)(7)(E)

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC
(b)(6);(b)(7)(C)

**SBF-CM
Folder Details**

Folder ID: 120810

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:.

Location: ODEQ
Due: 04/22/2012
Received: 4/12/2012
Date Sent: 4/19/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota increase request for oxycodone

Signature: Barbara Boockholdt

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/19/2012 4/18/2012

Action: Recommendation and Comments

Requested Activity:


Response Notes:

Memorandum



Subject <div style="border: 1px solid black; padding: 2px;">(b)(4);(b)(7)(E)</div> 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date APR 12 2012
---	--------------------------------

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From 
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

APR 18 2012

To

Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From

Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On April 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately forty-five (45) of (b)(4) customers as well as on (b)(4)

The following information was found on (b)(4) and the below listed customers:

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Because two of (b)(4) customers are currently under review/investigation, ODG recommends that ODQ adjust the quota allotted to (b)(4) accordingly.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

**SBF-CM
Folder Details**

Folder ID: 121176

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 05/11/2012
Received: 5/1/2012
Date Sent:

Security: A-AES

Response:

Abstract: Freedom Pharmaceuticals Inc 2012 procurement quota request oxycodone

Signature: C. Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

OD

05/08/2012 5/1/2012

Action: To Be Signed

Requested Activity:

Response Notes:

Memorandum



Subject

Freedom Pharmaceuticals, Inc. (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)


Date

MAY 1 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From


Christine A. Sannerud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject:

Freedom Pharmaceuticals (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN:630-08.2)

Date

MAY 01 2012

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 1, 2012, this section received your memorandum requesting a review of Freedom Pharmaceuticals' customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Freedom Pharmaceuticals provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

**SBF-CM
Folder Details**

Folder ID: 121262

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 05/13/2012
Received: 5/3/2012
Date Sent: 5/14/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota request for hydrocodone

Signature: J. Rannazzisi

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/10/2012 5/11/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	Date MAY 3 2012
---	-------------------------------

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From *Stacy Hays* /for
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	Date MAY 11 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and six (106) of (b)(4) (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company by at least the total kilogram amounts sold to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

SBF-CM
Folder Details

Folder ID: 121261

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location: ODEQ

Due: 05/13/2012

Received: 5/3/2012

Date Sent: 5/8/2012

Security: A-AES

Response:

Abstract: Aidarex 2012 procurement quota increase request for oxycodone

Signature: (b)(6);(b)(7)(C)

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/10/2012 5/7/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

4/27/2015 11:26:33 AM

1

Memorandum



Subject Aidarco (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date MAY 3 2012
--	------------------------

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From *Stacy Huppert* for
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

ODQ notes from the attached documents that this registrant has procured oxycodone finished dosage forms in 2011 and 2012 without a quota.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject

Aidarex (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN:630-08.2)

Date

MAY 07 2012

To

Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From

James Arnold
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of Aidarex's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Aidarex provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

SBF-CM Folder Details

Folder ID: 121263

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 05/13/2012
Received: 5/3/2012
Date Sent: 5/8/2012

Security: A-AES

Response:

Abstract: (b)(4) 2012 procurement quota increase request for oxycodone

Signature: (b)(6);(b)(7)(C)

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/10/2012 5/7/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

Memorandum



Subject

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

MAY 3 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From

Sally Hays /for
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject [redacted] 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date MAY 07 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
[Signature]
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of a quota increase submitted by [redacted] ODQ is requesting a review of [redacted] customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately twenty-three (23) of [redacted] customers as well as on [redacted]

The following information was found on one of [redacted] customer:

[redacted] **Currently Under Review/Investigation**
[redacted] (b)(4);(b)(7)(E)

Because one of [redacted] customers is currently under review/investigation, ODG recommends that ODQ adjust the quota allotted to [redacted] accordingly.

If you have any questions pertaining to this information, please feel free to contact me [redacted] or SC [redacted]
[redacted] (b)(6);(b)(7)(C)

SBF-CM Folder Details

Folder ID: 121412

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 05/20/2012
Received: 5/10/2012
Date Sent: 5/14/2012

Security: A-AES

Response:

Abstract: Sun Pharmaceutical Industries 2012 procurment qutoa increase request for hydrocodone / oxycodone

Signature: Christine Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/17/2012 5/14/2012

Action: Recommendation and Comments


Requested Activity:

Response Notes:

Memorandum



Subject Sun Pharmaceutical Industries, Inc. (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone / Oxycodone (DFN: 630-08.2)	Date MAY 10 2012
---	--------------------------------

To Barbara Boockholdt Chief Regulatory Section Office of Diversion Control	From  Christine A. Sannerud, Ph.D. Chief Drug & Chemical Evaluation Section Office of Diversion Control
---	---

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone and oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone and oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



<p>Subject</p> <p>Sun Pharmaceutical Industries, Inc. (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone/Oxycodone (DFN:630-08.2)</p>	<p>Date</p> <p>MAY 14 2012</p>
---	---------------------------------------

To

Christine A. Samnerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 10, 2012, this section received your memorandum requesting a review of Sun Pharmaceuticals' customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sun Pharmaceuticals provided a list of (b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. The check yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sun Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

5

**SBF-CM
Folder Details**

Folder ID: 121098

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 06/03/2012
Received: 5/24/2012
Date Sent:

Security: A-AES

Response:

Abstract: Sovereign 2012 procurement quota increase request for hydrocodone

Signature: J. Rannazzisi

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/31/2012 5/29/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

5/11/2015 2:36:33 PM

1

CMH bend - economy

Memorandum



5

Subject

Sovereign (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)


Date

MAY 24 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From


Christine A. Samerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

5

**SBF-CM
Folder Details**

Folder ID: 121635

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 06/03/2012
Received: 5/24/2012
Date Sent:

Security: A-AES

Response:

Abstract: Metrics Inc 2012 procurement quota increase request for oxycodone

Signature: Charistine Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/31/2012 5/29/2012

Action: Recommendation and Comments
Requested Activity:
Response Notes:

Memorandum



Subject

Metrics, Inc. (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)


Date

MAY 24 2012

To

Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From


Christine A. Sannerud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.

Memorandum



Subject

Metrics, Inc. (b)(4);(b)(7)(E)
2012 Procurement Quota Request
Oxycodone
(DFN:630-08.2)

Date

MAY 25 2012

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

Barbara J. Bookholdt
Barbara J. Bookholdt, Chief
Regulatory Section
Office of Diversion Control

On May 24, 2012, this section received your memorandum requesting a review of Metrics, Inc.'s customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Metrics, Inc. provided a list of (b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Metrics, Inc. for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	Date JUN 07 2012
--	--------------------------------

To
Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 5, 2012, this section received your memorandum requesting a review of (b)(4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

(b)(4) provided a list of ten (10) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

(b)(4);(b)(7)(E)

Retired 6/1/12

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by (b)(4) for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject

(b)(4)

2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

JUN 14 2012

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From

Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On June 7, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-five (95) of (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E)
Currently Under Review/Investigation

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(5);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E) **Retired**

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of (b)(4) customers are under Review/Investigation and one (1) is retired.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject Sovereign (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	Date JUN 27 2012
--	---------------------------------------

To
Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bookholdt
Barbara J. Bookholdt, Chief
Regulatory Section
Office of Diversion Control

On June 27, 2012, this section received your memorandum requesting a review of Sovereign's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sovereign provided a list of (b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sovereign for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject

Roadrunner Pharmacy (b)(4);(b)(7)(E)
2012 Procurement Quota
Hydrocodone
(DFN: 630-08.2)

Date

JUL 19 2012

To

Christine A. Sannerud, Ph.D., Chief
UN Reporting & Quota Section (ODQ)
Office of Diversion Control

From

Barbara J. Bockholdt
Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On July 17, 2012, this section received your memorandum requesting a review of a quota increase submitted by Roadrunner Pharmacy. ODQ is requesting a review of Roadrunner Pharmacy's customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately (b)(4) of Roadrunner's customers as well as an in-depth investigation of Roadrunner Pharmacy.

The below listed information was found on Roadrunner's customers:

NO DEROGATORY INFORMATION WAS FOUND

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Roadrunner Pharmacy for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject	Date
(b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN:630-08.2)	AUG 01 2012

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting & Quota Section
Office of Diversion Control

From *James A. ...*
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 17, 2012, this section received your memorandum requesting a review of (b)(4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

(b)(4) provided a list of five (05) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

(b)(4);(b)(7)(E)

Currently Under/Review Investigation
Currently Under/Review Investigation

DEA does not have sufficient grounds to limit, restrict, or deny a quota request from this registrant.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject [redacted] 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date AUG 22 2012
---	---------------------------------------

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bookholdt
Barbara J. Bookholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 2, 2012, this section received your memorandum requesting a review of a quota increase submitted by [redacted] ODQ is requesting a review of [redacted] customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately sixty one (61) of [redacted] customers as well as an in-depth investigation of [redacted]

The below listed information was found on [redacted] customers:

[redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company by at least the total kilogram amounts sold to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	Date SEP 10 2012
---	---------------------------------------

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 29, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-seven (97) of (b)(4) customers as well as an in-depth investigation of (b)(4).

The below listed information was found on (b)(4) customers:

Order to Show Cause Requested to CC
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

(b)(4);(b)(5)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Ten (10) of (b)(4) customers are under Review/Investigation.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

Memorandum



Subject Mikart Inc. (DEA (b)(4);(b)(7)(E)) 2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	Date SEP 12 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Bookholdt
Barbara J. Bookholdt, Chief
Regulatory Section
Office of Diversion Control

On September 11, 2012, this section received your memorandum requesting a review of Mikart Inc.'s customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Mikart Inc. provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum



Subject	Date
(b)(4);(b)(7)(E)	
2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	SEP 17 2012

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On September 10, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred fifty-nine (159) of (b)(4) customers as well as on (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E)

Retired in 7/2012

Retired 7/05/2012

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Two of (b)(4) customers are currently retired and three (3) customers are under review/investigation.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C).

Memorandum



Subject <div style="border: 1px solid black; padding: 2px;">(b)(4);(b)(7)(E)</div> 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date SEP 17 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 31, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-six (96) of (b)(4) customers as well as an in-depth investigation of (b)(4)

(b)(4);(b)(7)(E)

The below listed information was found on (b)(4) customers:

- Currently Under Review/Investigation**
- Currently Under Review/Investigation**
(b)(4);(b)(7)(E)
- Currently Under Review/Investigation**
(b)(4);(b)(7)(E)
- Currently Under Review/Investigation**
(b)(4);(b)(5);(b)(7)(E)
- Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Retired**

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Ten (10) of (b)(4) customers are under Review/Investigation and one (1) is retired.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date OCT 31 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt,
Chief
Regulatory Section
Office of Diversion Control

On September 18, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

(b)(4);(b)(7)(E)

ODGR conducted NADDIS and CSA reviews of approximately one hundred and seventy two (172) of (b)(4) customers as well as an in-depth investigation of

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Suspension**

(b)(4);(b)(7)(E) **Currently Under Under/Review**

(b)(4);(b)(7)(E) **Currently Under Under/Review**

(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(5);(b)(7)(E)

(b)(4);(b)(7)(E)

RETIRED 9/30/2011

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
Currently Under Suspension

[Redacted] **Currently Under Review/Investigation**
 (b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. [Redacted]

[Redacted] and Sixteen (16) of (b)(4) customers are under **Currently Under Review/Investigation**, Two (2) are **Currently Under Suspension**, and one (1) is **Retired** (b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date NOV 01 2012
---	--------------------------------

To
Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt,
Chief
Regulatory Section
Office of Diversion Control

On September 27, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and nine (109) of (b)(4) (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

- Currently Under Review/Investigation**
(b)(4);(b)(7)(E) (b)(4);(b)(7)(E)
- Order to Show Cause Requested** (b)(4);(b)(7)(E)
- Currently Under Review/Investigation** (b)(4);(b)(7)(E)
- Currently Under Review/Investigation**
(b)(4);(b)(5);(b)(7)(E)
- Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Retired 6/5/2012**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Suspension**

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of (b)(4) customers are under Review/Investigation, one (1) has been issued an Order to Show Cause (OTSC), one (1) is Under Suspension and one (1) is Retired (b)(4);(b)(7)(E)

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Memorandum



<p>Subject</p> <p>(b)(4);(b)(7)(E)</p> <p>2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)</p>	<p>Date</p> <p>NOV 09 2012</p>
---	--------------------------------

To

Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From

[Signature] 11.9.12
Barbara J. Boeckholdt,
Chief
Regulatory Section
Office of Diversion Control

On October 18, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred forty-four (144) of (b)(4) (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

- (b)(4);(b)(7)(E) **Currently Under Review/Investigation**
- (b)(4);(b)(7)(E) **Currently Under Review/Investigation**
- (b)(4);(b)(7)(E) **Currently Under Review/Investigation**
- (b)(4);(b)(7)(E) **Currently Under Review/Investigation**
- (b)(4);(b)(7)(E) **Currently Under Review/Investigation**

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(5);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

[Redacted] **Currently Under Review/Investigation**
(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of (b)(4) customers are under Review/Investigation, (b)(4);(b)(5);(b)(7)(E)

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Cc: ChristineASannerud, Ph.D /Chief/ODQ/UN Reporting and Quota Section

Cc: ODG

Cc: ODGR (b)(6);(b)(7)(C) 11/9/2012: ReqDoc:10/18/2012

Memorandum



Subject (b)(4);(b)(7)(E) 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date NOV 29 2012
--	-------------------------

To
Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt,
Chief
Regulatory Section
Office of Diversion Control

On November 13, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) OIQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately fifty- nine (59) of (b)(4) customers as well as an in-depth investigation of (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(5);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Review/Investigation**

(b)(4);(b)(7)(E) **Currently Under Suspension**

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Three (3) of (b)(4) customers are under Review/Investigation, one (1) is currently Under Suspension.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Memorandum



Subject <div style="border: 1px solid black; padding: 2px;">(b)(4);(b)(7)(E)</div> 2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	Date <p style="text-align: center;">NOV 29 2012</p>
---	--

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Boockholdt
Barbara J. Boockholdt, Chief
Regulatory Section/ODG
Office of Diversion Control

On November 28, 2012, this section received your memorandum requesting a review of

(b)(4)

 customer list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

(b)(4)

 provided a list of one (1) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. ODGR has checked with the DEA/

(b)(7)(E)

 on this matter. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

(b)(4);(b)(7)(E)

At this time it does not appear that DEA has sufficient legal grounds to limit, restrict, or deny quota requests from this registrant. Based on this information, ODG suggests that you proceed with the completion of the request submitted by

(b)(4)

 for an increase of their quota.

If you have any questions pertaining to this information, please feel free to contact me

(b)(6);(b)(7)(C)

 or PA

(b)(6);(b)(7)(C)